Coherus Announces Positive Interim Results From Phase 3 Trial On Non-Small Cell Lung Cancer

(RTTNews) - Coherus BioSciences Inc. (CHRS) and Shanghai Junshi Biosciences Co., Ltd. announced positive interim results from a phase 3 clinical trial, which evaluated toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer or NSCLC.

The interim analysis from the pivotal study "CHOICE-01" (NCT03856411) met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival per RECIST v1.1 compared to chemotherapy alone.

The interim results will be presented on September 13 at IASLC 2021 World Conference on Lung Cancer.

The company expects to pursue registration for toripalimab for a broad array of indications in China, the United States and other markets.